Micol received her MD in 2012 and completed her residency in Neurology in 2018 at the University of Pavia, Italy. She is currently working as neurologist at IRCCS Mondino Foundation, Pavia, and she is completing her PhD in Neuroscience at the Department of Brain and Behavioural Sciences, University of Pavia under the supervision of Prof. C. Tassorelli. Micol has recently worked at the Department of Clinical and Movement Neurosciences, UCL, London, UK, under the supervision of Prof. AH. Schapira. During this period, she conducted her research on the GBA mutation carriers and gained experience in the clinical assessment of these subjects and enriched her profile with a direct experience ‘at the bench’ on cell cultures and enzyme assays. Since 2017, she also collaborates with Prof. EM. Valente and she is focusing her research on the genetic basis of Parkinson’s Disease to better understand the genotype-phenotype correlation in order to identify reliable biomarkers to improve clinical management and treatment of PD patients.
Micol Avenali, MD
University of Pavia
Micol received her MD in 2012 and completed her residency in Neurology in 2018 at the University of Pavia, Italy. She is currently working as neurologist at IRCCS Mondino Foundation, Pavia, and she is completing her PhD in Neuroscience at the Department of Brain and Behavioural Sciences, University of Pavia under the supervision of Prof. C. Tassorelli. Micol has recently worked at the Department of Clinical and Movement Neurosciences, UCL, London, UK, under the supervision of Prof. AH. Schapira. During this period, she conducted her research on the GBA mutation carriers and gained experience in the clinical assessment of these subjects and enriched her profile with a direct experience ‘at the bench’ on cell cultures and enzyme assays. Since 2017, she also collaborates with Prof. EM. Valente and she is focusing her research on the genetic basis of Parkinson’s Disease to better understand the genotype-phenotype correlation in order to identify reliable biomarkers to improve clinical management and treatment of PD patients.
